<DOC>
	<DOCNO>NCT01184807</DOCNO>
	<brief_summary>This open-label , non-randomized , dose-escalation trial patient advance solid tumor . The trial comprise 2 stage : dose escalation stage 8 dose level 2 , 5 , 10 , 20 , 40 , 60 , 80 , 100 mg/day , possibly additional intermediate dos , determine MTD recommend dose , subsequent 2 part expansion stage investigate safety profile antitumor effect OPB-51602 recommend dose .</brief_summary>
	<brief_title>Phase 1 , Dose-escalation Trial OPB-51602 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>In expansion stage part 1 , 20 advance sell tumor subject investigate safety profile antitumor effect OPB-51602 recommend dose 3 week per cycle（2 week treatment 1 week washout ) . In expansion stage part 2 , maximum 20 subject Non-small cell lung cancer ( NSCLC ) , Melanoma Gastrointestinal Stromal Tumor ( GIST ) treat investigational Medicinal product ( IMP ) efficacious case find . subject dosing start Day 1 without 2-day treatment free interval continue Day 28 recommend dose ( 4mg ) first cycle 1 . After safety tolerability confirm , subject treat MTD ( 5mg ) cycle 2 onwards once-daily oral dose 4 week per cycle obtain additional information safety , tolerability antitumor activity OPB-51602</detailed_description>
	<criteria>Patients pathologically confirm , locally advanced metastatic solid tumor unresponsive standard therapy standard therapy intolerable unsuitable Age : ≥21 year ( time inform consent ) ECOG performance status : ≤2 ( Appendix 1 ) Life expectancy longer 3 month Adequate vital organ function follow : 1 . Bone marrow function Neutrophils : ≥1,500/μL , platelet : ≥75,000/μL , hemoglobin : ≥9.0 g/dL 2 . Hepatic function Aspartate transaminase ( AST ) alanine transaminase ( ALT ) : ≤2.5 ×institutional upper limit normal ( ULN ) ≤5.0 × institutional ULN liver metastasis , serum total bilirubin : &lt; 2.5 × institutional ULN 3 . Renal function Serum creatinine : &lt; 1.5 × institutional ULN Capable swallow OPB51602 tablet Ability understand willingness sign write informed consent form ( ICF ) participation trial No chemotherapy , radiotherapy , surgery , immunotherapy , therapy within 4 week prior start investigational medicinal product ( IMP ) administration recover prior toxicity If subject receive 5 regimen previous chemotherapy , investigator must discuss sponsor regard subject suitability prior enrollment . Uncontrolled central nervous system ( CNS ) metastasis Uncontrolled concurrent illness , include active infection , angina pectoris , cardiac arrhythmia , heart failure ( NYHA class III IV , Appendix 2 New York Heart Association ( NYHA ) functional classification ) Concurrent malignancy different type Immunocompromised subject , include know infected human immunodeficiency virus ( HIV ) Psychiatric illness would limit compliance trial requirement Pregnant breastfeed woman Women childbearing potential ( WOCBP ) male subject whose partner WOCBP use effective contraceptive measure Administration another investigational agent within 6 week prior start IMP administration Use prohibit medication substance list Appendix 3 CYP3A4 Inhibitors Inducers within either 1 week prior start IMP administration period least 5 time respective elimination halflife , whichever long Known severe gastrointestinal disorder , include malabsorption ( screen ) Patients CTCAE Grade 1 high pneumonitis ( interstitial pneumonia ) pulmonary fibrosis* * If interstitial lung abnormality , ( e.g . groundglass linear opacity ) suspect chest CT scan ( highresolution CT ) , regardless whether accompany symptom must confirm , consultation respiratory radiology expert necessary , patient dose fall exclusion criterion patient enrol trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Advanced solid tumor</keyword>
</DOC>